Taliglucerase alfa is a plant-derived enzyme that is currently (as of February 2011) in phase III clinical trials by Protalix and Pfizer.[1] The enzyme is a recombinant glucocerebrosidase used to treat Gaucher’s Disease. If it is approved by the U.S. Food and Drug Administration it will be first plant-made pharmaceutical.[2] Expression of proteins in plant cell culture is highly efficient, does not require post-expression modification of the protein, and is not susceptible to contamination by agents such as viruses that are pathological to humans.[3] Using transgenic carrot cells produces a lower cost alternative, and preclinical studies show that the enzyme was well tolerated by patients.[4]